Introduction:
In a recent ruling, the Delhi High Court dismissed a petition that sought to compel the Homeopathic Pharmacopoeia Laboratory (HPL) of the Ministry of Ayush to analyze certain homeopathic prescriptions. This analysis was intended to aid the Inter-Departmental Committee of the Ministry of Health and Family Welfare in deciding on the recognition of Electro Homeopathy as an alternative system of medicine. The case highlights the judiciary’s stance on non-interference in policy matters and underscores the established protocols for recognizing alternative medical systems.
The Ministry of Health and Family Welfare constituted an Inter-Departmental Committee to evaluate the viability and recognition of various alternative medicine systems, including Electro Homeopathy. The Homeopathy Pharmacopoeia Laboratory (HPL) functions as a national laboratory responsible for setting standards and testing homeopathic medicines as per the Drugs and Cosmetics Act, 1940.
During a committee meeting held on February 19, 2021, it was concluded that Electro Homeopathy lacked sufficient scientific data to facilitate a proper evaluation of its potential as an alternative medical system. The petitioner argued that the German Homeopathic Pharmacopoeia, recognized under the Second Schedule of the Drugs and Cosmetics Act, includes prescriptions by Krauss and Zimpel, which are foundational to Electro Homeopathy. The petitioner claimed that analyzing these prescriptions would assist the committee in determining the viability of Electro Homeopathy.
Arguments of Both Sides:
The petitioner contended that the German Homeopathic Pharmacopoeia, acknowledged under the Drugs and Cosmetics Act, includes the Krauss and Zimpel prescriptions, which are essential for manufacturing Electro Homeopathic remedies. The petitioner argued that since tinctures essential for these remedies cannot be produced without proper analysis, the HPL should analyze the Krauss and Zimpel prescriptions. This analysis would enable the Inter-Departmental Committee to assess Electro Homeopathy’s potential as an alternative system of medicine. The petitioner further argued that the HPL has an obligation to conduct such analysis under the Drugs and Cosmetics Act.
The respondents, represented by the Ministry of Health and Family Welfare and the Homeopathic Pharmacopoeia Laboratory, argued that the recognition of a new or alternative system of medicine is a matter of policy, which falls outside the judiciary’s purview. They maintained that the HPL is mandated only to perform functions specified under the Drugs and Cosmetics Act and related rules. Clinical studies or analysis of electro-homeopathic medicines are not included within these functions. Furthermore, the respondents asserted that since Electro Homeopathy is not covered under Rule 2(dd) or the Second Schedule of the Drugs and Cosmetics Act, the HPL is not obliged to analyze these medicines. They also pointed out that the Inter-Departmental Committee’s decision not to accept individual applications is a policy matter that does not warrant judicial interference.
Court’s Judgement:
Justice Subramonium Prasad delivered the judgment, reiterating that the recognition of a new or alternative system of medicine is a matter of policy. The Court referenced the Supreme Court’s decision in Academy of Nutrition Improvement & Ors. v. Union of India (2011 AIR SCW 6281), which established that courts should generally refrain from interfering with government policy decisions on public health, particularly those based on expert input and thorough research. The Supreme Court had emphasized that courts do not substitute their own views for those of qualified professionals and experts in policy matters.
In this context, the Court held that the HPL is only required to perform functions outlined under the Drugs and Cosmetics Act and its rules. Since clinical studies and the analysis of electro-homeopathic medicines are not covered under its purview, the HPL is not obliged to analyze these medicines. The Court observed that since Electro Homeopathy is not included in Rule 2(dd) or the Second Schedule of the Act, the analysis of these medicines does not fall within HPL’s responsibilities.
The Court also upheld the Inter-Departmental Committee’s stance on not accepting applications from individuals, suggesting that the petitioner should collaborate with other organizations advocating for the recognition of Electro Homeopathy as a new or alternate form of medicine.
The Court thus dismissed the petition, affirming that the matter of recognizing new medical systems is purely a policy decision and beyond the judiciary’s scope of interference.